Hester Biosciences Limited (BOM:524669)
India · Delayed Price · Currency is INR 2,409.90
+13.15 (0.55%)
At close: Jul 15, 2026
Hester Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 3,326 | 3,111 | 3,045 | 2,661 | 2,350 |
Other Revenue | 15.22 | 13.72 | 66.48 | 121.14 | 116.41 |
| 3,341 | 3,125 | 3,112 | 2,782 | 2,466 | |
Revenue Growth (YoY) | 6.93% | 0.41% | 11.86% | 12.80% | 13.30% |
Cost of Revenue | 876.61 | 928.37 | 997.28 | 824.81 | 678.19 |
Gross Profit | 2,465 | 2,196 | 2,115 | 1,957 | 1,788 |
Selling, General & Admin | 727.14 | 728.49 | 752.69 | 675.39 | 516.02 |
Other Operating Expenses | 772.43 | 843.64 | 758.94 | 654.62 | 536.16 |
Operating Expenses | 1,772 | 1,740 | 1,683 | 1,537 | 1,238 |
Operating Income | 692.99 | 456.22 | 431.29 | 420.28 | 550.43 |
Interest Expense | -74.16 | -83.4 | -91.19 | -51.49 | -25.76 |
Interest & Investment Income | 15.79 | 20.37 | 19.07 | 21.73 | 19.03 |
Earnings From Equity Investments | 63.73 | 41 | 46.09 | 44.09 | 4.23 |
Currency Exchange Gain (Loss) | 19.17 | -33.62 | -94.68 | -29.92 | -4.59 |
Other Non Operating Income (Expenses) | -6.09 | -4.86 | -3.1 | -3.31 | -9.57 |
EBT Excluding Unusual Items | 711.43 | 395.71 | 307.48 | 401.38 | 533.77 |
Gain (Loss) on Sale of Investments | 17.57 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | - | 0.28 | 0.16 | 1.25 |
Other Unusual Items | 29.36 | - | 11.77 | - | - |
Pretax Income | 758.36 | 395.71 | 319.53 | 401.54 | 535.02 |
Income Tax Expense | 183.52 | 107.45 | 107.87 | 121.19 | 140.18 |
Earnings From Continuing Operations | 574.84 | 288.26 | 211.66 | 280.35 | 394.84 |
Minority Interest in Earnings | -18.45 | -13.38 | -22.77 | -14.08 | -1.64 |
Net Income | 556.39 | 274.88 | 188.89 | 266.27 | 393.2 |
Net Income to Common | 556.39 | 274.88 | 188.89 | 266.27 | 393.2 |
Net Income Growth | 102.41% | 45.52% | -29.06% | -32.28% | 14.20% |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 |
EPS (Basic) | 65.40 | 32.31 | 22.20 | 31.30 | 46.22 |
EPS (Diluted) | 65.40 | 32.31 | 22.20 | 31.30 | 46.22 |
EPS Growth | 102.41% | 45.52% | -29.06% | -32.28% | 14.20% |
Free Cash Flow | 463.13 | 439.2 | 237.86 | -541.66 | -869.98 |
Free Cash Flow Per Share | 54.44 | 51.63 | 27.96 | -63.67 | -102.27 |
Dividend Per Share | 11.000 | 7.000 | 6.000 | 8.000 | 10.000 |
Dividend Growth | 57.14% | 16.67% | -25.00% | -20.00% | - |
Gross Margin | 73.76% | 70.29% | 67.95% | 70.35% | 72.50% |
Operating Margin | 20.74% | 14.60% | 13.86% | 15.11% | 22.32% |
Profit Margin | 16.65% | 8.80% | 6.07% | 9.57% | 15.94% |
Free Cash Flow Margin | 13.86% | 14.06% | 7.64% | -19.47% | -35.27% |
EBITDA | 816.73 | 562.6 | 599.98 | 624.22 | 712.92 |
EBITDA Margin | 24.44% | 18.00% | 19.28% | 22.44% | 28.90% |
D&A For EBITDA | 123.74 | 106.38 | 168.69 | 203.94 | 162.49 |
EBIT | 692.99 | 456.22 | 431.29 | 420.28 | 550.43 |
EBIT Margin | 20.74% | 14.60% | 13.86% | 15.11% | 22.32% |
Effective Tax Rate | 24.20% | 27.15% | 33.76% | 30.18% | 26.20% |
Revenue as Reported | 3,423 | 3,150 | 3,152 | 2,812 | 2,487 |
Advertising Expenses | 70.48 | 77.73 | 88.06 | 99.74 | 49.63 |